Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adenocarcinoma of the Pancreas: early-phase trial registry
2 of 11 indexed Adenocarcinoma of the Pancreas trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 2 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Adenocarcinoma of the Pancreas: 11 US clinical trials tracked, 2 recruiting.
Adenocarcinoma of the Pancreas is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition adenocarcinoma-of-the-pancreas
OPEN 2 | RECR 18% | LATE 1 | EARLY 9 | RANK #1577 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (18% recruiting · 22 trials)
Adenocarcinoma of the Pancreas lists 2 open slots (18% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adenocarcinoma of the Pancreas on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adenocarcinoma of the Pancreas is recruiting below its size-band peers.
2 of 11 indexed trials (18.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Adenocarcinoma of the Pancreas research.
National Cancer Institute (NCI) accounts for 5 of 11 trials (45.5%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Adenocarcinoma of the Pancreas trials plan to enrol fewer than 100 people.
Median target enrolment is 35 among the 11 trials that report a genuine target (sentinel values excluded). 10 of those (90.9%) plan for fewer than 100 participants.
-
Adenocarcinoma of the Pancreas research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma
West Virginia University
NCT04911816
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Gulam Manji
NCT04543071
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT00088894
SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma
David A. Clump, MD, PhD
NCT01357525
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
NCT00028496
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT00075647
Perioperative Therapy for Resectable Pancreatic Cancer
University of Washington
NCT00609336
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
Massachusetts General Hospital
NCT00366457
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Roswell Park Cancer Institute
NCT01497392
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
National Cancer Institute (NCI)
NCT01232829
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT00331682
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Adenocarcinoma of the Pancreas records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adenocarcinoma of the Pancreas trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adenocarcinoma of the Pancreas page
11 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Adenocarcinoma of the Pancreas trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Adenocarcinoma of the Pancreas trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adenocarcinoma of the Pancreas condition card totals 11 registered trials; most-linked intervention gemcitabine hydrochloride; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.